Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0480-0389 with semaglutide safety, tolerability, pharmacokinetics, and pharmacodynamics study
NL-OMON55332Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 1 trial of NNC0480-0389 and semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Started Feb 2020; status: completed.
02
Drugs
NNC0480-0389semaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON55332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55332.